Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment
Background. Currently, treatment of recurrent / refractory chronic lymphocytic leukemia (CLL) involves the appointment of regimens with innovative drugs, which include ibrutinib and a combination of venetoclax and rituximab. Wherein said combination provides continuing over time high frequency eradi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-04-01
|
| Series: | Onkogematologiâ |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/408 |